首页> 外文期刊>Current pharmaceutical design >Breast cancer biomarkers: Risk assessment, diagnosis, prognosis, prediction of treatment efficacy and toxicity, and recurrence
【24h】

Breast cancer biomarkers: Risk assessment, diagnosis, prognosis, prediction of treatment efficacy and toxicity, and recurrence

机译:乳腺癌生物标志物:风险评估,诊断,预后,预测治疗疗效和毒性,以及复发

获取原文
获取原文并翻译 | 示例
           

摘要

Breast cancer is the most common cancer amongst women in the United States and around the world. Although widespread use of adjuvant chemotherapeutic and hormonal agents has improved mortality from breast cancer, it remains challenging to determine on an individual basis who will benefit from such treatments and who will be likely to encounter toxicities. With the rising costs of healthcare and the introduction of new targeted therapies, use of biomarkers has emerged as a method of assisting with breast cancer diagnosis, prognosis, prediction of therapeutic response, and surveillance of disease during and after treatment. In the following review, prognostic and therapeutic biomarkers, their utility in the management of patients with breast cancer, and current recommendations regarding their clinical use will be discussed.
机译:乳腺癌是美国和世界各地的女性中最常见的癌症。 尽管佐剂化学治疗和激素剂的广泛使用来自乳腺癌的死亡率提高了,但是根据这些治疗中受益的个别基础并可能会遇到毒性的个人基础,它仍然具有挑战性。 随着医疗保健成本的上升和新的目标疗法的引入,使用生物标志物作为辅助乳腺癌诊断,预后,治疗反应预测的方法,以及治疗期间和后疾病的监测。 在下列审查中,预后和治疗生物标志物,他们在乳腺癌患者管理中的效用以及将讨论关于其临床使用的目前的建议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号